SCHEMBL26075919

SCHEMBL26075919

COCc1ccccc1-c1ccc(-c2cc(C(=O)O)c3cc(C)ccc3n2)cc1F

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.56
▸ ALDH1A1 P00352 2/20 0.56
▸ HSD17B10 Q99714 1/20 0.56
▸ DHODH Q02127 9/20 0.52
▸ MAPT P10636 5/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ POLB P06746 1/20 0.49
▸ LMNA P02545 1/20 0.48
▸ TP53 P04637 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ S1PR1 P21453 1/20 0.47
▸ S1PR3 Q99500 1/20 0.47
▸ MEN1 O00255 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23590274 0.91 DHODH (0.58) KDM4EALDH1A1HSD17B10DHODHMAPT
SCHEMBL23590137 0.88 DHODH (0.47) KDM4EALDH1A1HSD17B10DHODHMAPT
SCHEMBL26075396 0.86 DHODH (0.44) KDM4EALDH1A1HSD17B10DHODHMAPT
SCHEMBL26075914 0.84 KDM4E (0.55) KDM4EALDH1A1HSD17B10DHODHMAPT
SCHEMBL29617665 0.81 DHODH (0.66) KDM4EALDH1A1HSD17B10DHODHKMT2A
SCHEMBL23590322 0.81 DHODH (0.66) KDM4EALDH1A1HSD17B10DHODHKMT2A
SCHEMBL26075922 0.81 DHODH (0.66) KDM4EALDH1A1HSD17B10DHODHMAPT
SCHEMBL26075925 0.80 KDM4E (0.61) KDM4EALDH1A1HSD17B10DHODHMAPT
SCHEMBL26075310 0.79 DHODH (0.42) DHODHKMT2AS1PR1S1PR3MEN1
SCHEMBL26075954 0.79 DHODH (0.52) KDM4EALDH1A1HSD17B10DHODHMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018108-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2024-01-18 — — US disclosed
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD KDM4E 1396/4885ALDH1A1 88/4885HSD17B10 130/4885
US-20240018108-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DLD, FAH KDM4E 580/4885ALDH1A1 56/4885HSD17B10 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback